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Edited by Laszlo NagyAbstract Sterol regulatory element binding protein (SREBP)-
1a is a transcription factor that is highly expressed in actively
growing cells, and is involved in the biosynthesis of cholesterol,
fatty acids and phospholipids. We have mapped the minimal
human SREBP-1a promoter region to 75 bp upstream of the trans-
lation start site where we discovered a functional role for the 3
GC-boxes containing overlapping sites for the Sp1 and EGR-1
transcription factors. Intact SP1-binding sites are essential for
promoter activity, whereas EGR-1 suppresses the transcription
of the human SREBP-1a promoter. These results reveal a novel
physiologically relevant transcriptional mechanism for the reci-
procal regulation of the SREBP-1a expression.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cell line1. Introduction
Sterol regulatory element binding proteins (SREBPs) are
members of the basic helix–loop–helix family of transcription
factors that directly activate the expression of those genes
involved in cholesterol and fatty acid metabolism [1]. The
SREBP-1 gene encodes two almost identical proteins,
SREBP-1a and SREBP-1c, which are expressed from overlap-
ping mRNAs. A separate gene encodes a third isoform,
SREBP-2 [2]. SREBP-1a is the predominant isoform in most
cultured cell lines, spleen and intestine, whereas SREBP-1c
predominates in the liver and in most other tissues, such as
muscle and adipose tissue [3]. These data indicate that those
promoters that control SREBP-1 mRNAs initiation not only
respond independently to organ-speciﬁc factors, but also to
metabolic stresses.
The responsible promoter regions associated with the basal
transcription of the mouse SREBP-1a promoter have beenAbbreviations: ChIP, chromatin immunoprecipitation; egr-1, early
growth response gene 1; EGR-1, the early growth response 1 protein;
EMSA, electrophoretic mobility-shift assay; HEK293T cells, human
embryonic kidney 293T cells; NFjB, nuclear factor kappa B; SREBP,
sterol regulatory element binding protein
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doi:10.1016/j.febslet.2007.11.083identiﬁed. The promoter for mouse SREBP-1a is contained
in a very small promoter-proximal region encompassing two
binding sites for transcription factor SP1 that are essential
for promoter activity. These two SP1 sites reside in a region
that is highly conserved within the human gene, emphasizing
these important cis-acting DNA elements [4]. In many promot-
ers, SP1 sites overlap with binding sites for the early growth re-
sponse 1 protein (EGR-1). This transcriptional factor, also
known as Zif268, NGFI-A, Krox24 or TIS8, is able to either
activate or repress the transcription of gene promoters at their
GC-rich elements [5]. Moreover, the early growth response
gene 1 (egr-1) expression augments the SP1 activation of
non-overlapping SP1+EGR-1 sites, but inhibits SP1 activity
when sites overlap by competing with SP1 for the binding site
[6].
The lack of detailed experimental data in the human
SREBP-1a promoter prompted us to not only investigate the
responsible regions in the 5 0 ﬂanking region of the human
SREBP-1a promoter, but also the transcription factors associ-
ated with the human SREBP-1a transcript expression. We
mapped the basal promoter to 75 bp upstream of the ATG
start codon and demonstrated a functional role for three
GC-boxes containing overlapping EGR-1 and SP1 binding
sites. Therefore, both these factors are implicated in the regu-
lation of the human SREBP-1a promoter.2. Materials and methods
2.1. Construction of the human SREBP-1a-lucifersase promoter
plasmids
Two fragments containing 1545 bp and 1202 bp, corresponding to
the 5 0 upstream region of the human SREBP-gene, were ampliﬁed
by PCR and cloned into pGEMTeasy vector (Promega, Madison,
USA) to construct the pSPro-easy and pPro-easy vectors, respectively.
The 2553, 1648, 1008, 889, 717, 360 and 75/+194luc
plasmids were obtained by releasing restriction fragments from the
pSPro-easy and pPro-easy constructs followed by subcloning into the
pGL3-basic vector (Promega). Mutagenesis was performed by using
the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA, USA), where pPro-easy was deployed as a template. All plasmids
were conﬁrmed by nucleotide sequencing. Vectors pcDNA3-Egr1
(Addgene plasmid 11729), pEBS14luc, pCMV-Sp1 (Addgene plasmid
12097) and pAld-GCB4 were previously described [5,7].
2.2. Cell culture and luciferase assay
Human embryonic kidney 293T cells (HEK293T cells) were cultured
in DMEM containing 25 mmol/l glucose, 100 U/ml penicillin, and
100 lg/ml streptomycin supplemented with 10% foetal bovine serum.blished by Elsevier B.V. All rights reserved.
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Lipofectamine 2000 (Invitrogen, Carlsbad, CA. USA) with 850 ng of
SREBP-1a reporter plasmids and 50 ng of a Renilla luciferase con-
struct (pRL-TK) as an internal control. In some experiments, cells
were co-transfected with 200 ng of luciferase vectors, 100 ng of
pcDNA3-Egr1 or pCMV-Sp1 expression vector and 20 ng of pRL-
TK. Transactivation activities were measured 24 h after transfection
in a Wallac 1420 VICTOR luminometer according to the technical
manual of the Dual-Luciferase Reporter Assay System (Promega).
In the RNAi experiments, HEK293T cells were co-transfected with
100 nM of synthetic pre-designed short interfering RNA (siRNA)
against human egr-1 (siRNA ID#: 146223), human sp1 (siRNA ID#
116547 and # 143158) or silencer negative control siRNA (Ambion,
Austin, TX), with 800 ng of 75/+194luc plasmid and 40 ng of pRL-
TK using Lipofectamine 2000 in Opti-MEM 1 medium (Invitrogen)
according to the manufacturers instructions. After 48 h of incubation,
luciferase activities were determined as described above. The Egr-1, Sp-
1 and SREBP-l levels were monitored by RT q-PCR using the second
derivative comparative Ct method. The primer sets and Taqman
probes used to analyze cDNA were proprietary to Applied Biosystems
(Assays-on-demand gene expression product; Applied Biosystems Fos-
ter City, CA, USA).
2.3. RT-PCR
Total RNA was isolated from HeLa, HEK293T or HepG2 cells
using Trizol reagent (Invitrogen). First strand cDNA was synthesized
from 1 lg of total RNA using random hexamer and expand reverse
transcriptase (Roche Diagnostics, Manheim, Germany). cDNA was
used as a template for conventional PCR, using speciﬁc primers of hu-hSREBP -1a
hSREBP -1c
HeLa HEK
293T
HepG2
-2553/+194
-1008/+194
-889/+194
-717/+194
-360/+194
-75/+194
-1648/+194
pGL3-basic 1
GAPDH
Fig. 1. Characterization of the early promoter region of the human SREB
subjected to RT-PCR. The expression of SREBP-1c was barely detectable in
on the left-hand side, were ligated into the multiple cloning regions of the pGL
relative to pGL3-basic vector (±S.E.M.), and normalized to renilla lucifer
transfections run in duplicate.man SREBP-1 isoforms (sequence upon request). The GAPDH expres-
sion was measured as an endogenous control.
2.4. Electrophoretic mobility shift assays (EMSA)
Nuclear extracts from the HEK293T cells transfected with pcDNA3-
egr1 were prepared as previously described [8]. EMSA were performed
using double-stranded DNA oligonucleotides that were end-labelled
with [c-32P]ATP as described in [9]. Binding reactions were carried
out for 20 min at room temperature using recombinant human SP1
protein (Promega), human EGR-1 protein synthesized from pcDNA3
expression vectors using the TNT T7-coupled reticulocyte lysate sys-
tem (Promega) or nuclear extracts, 9 fmol of probe, 2 lg dI/dC in
the binding buﬀer and 6 lg BSA. Supershifts were obtained by adding
speciﬁc antibodies to the reaction mix for 1 h on ice before adding the
probe. For the competition experiments, a 25-fold excess of unlabelled
oligonucleotide was added to the reaction mixture. DNA–protein com-
plexes were resolved on 6% (w/v) non-denaturing polyacrylamide gels
in 0.5· TBE buﬀer (1· TBE is 90 mM Tris, 90 mM boric acid and
1 mM EDTA).
Protein analysis was carried out by Western blot as previously de-
scribed [10] using antibodies to EGR-1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
2.5. Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) and RNApol-ChIP proce-
dures, using isolated nuclei from formaldehyde cross-linked HEK293T
cells, were performed according to Sandoval et al. [11]. Brieﬂy, isolated
nuclei from formaldehyde cross-linked cell cultures were lysed and
chromatin was sonicated in a Vibra-Cell VCX-500 sonicator to yield0 5 10 15 20
Fold Activation
HEK293 cells 
P-1a gene. (A) Total RNA was puriﬁed from diﬀerent cell lines and
HEK293T cells. (B) The sequences in the SREBP-1a promoter, shown
3-basic vector and transfected into HEK293T cells. The fold induction
ase data, was calculated. The results shown are the average of four
rSREBP-1a       GTGAGTTTCCTGTTCTCTGCTCCCACCCTTACGCCGGCACCCCC-TCCCTGGCCCTTTAG   
mSREBP-1a       GTGAGTTTTCTGTTCTCTGCTCCCACCCTCATGCTGGGCCCCCCATCCCTGGCCCTTTAA   
hSREBP-1a       AAGTTTGGGATGGGCCCAGGCCTGGGGCTTCCACTCGGCTTCCT-TGCTTGGTGCTGGAG -251 
                  *  *    **  * * *  *     **    *  *    **  * * ***  **     
 
rSREBP-1a       TCTAACGATGTCTGGGCTAGGTCTAG------------TCCTGTGGCTTCCATT----GG  
mSREBP-1a       TCTAACGATGTCTGGGCTGGGTCTAG------------TCCTGTGGCTTCCATTC---GG  
hSREBP-1a       AAACAGAGGCCCAGAGAGGGGGCTCGGCTTGCCCGCGTTCCCGCAGCAGCCGGCCAGAGG -191 
                    *      * * *   ** ** *            *** *  **  **       ** 
 
rSREBP-1a       AC---CCCTTGCCCTGGTG---CTGAAGAAACCCAGGCCCCGTGTCTGGGCACCCGCAGG  
mSREBP-1a       TCCCTCCCTTGGCCTGATA---CAGAAGAAGCCAAGGCCCAGTGCCTGTGCACCCGCAGG  
hSREBP-1a       CCGCTGCCATTGTGCGCGAGGCTGGATAAAATGAATGACTGGAGGGCGCTCTGGAGGAGG -131 
                 * ** ** *     *        **  **    * * *    *   *  *    * *** 
 
rSREBP-1a       AGGTGGCGGGAAAC------------CAGGCTCTGG--TAAGCAGTCTGAACCCGCT—-A  
mSREBP-1a       AGATTGCTAGAAAC------------CAGGCTCGGG--CAGGCAGTCTCAACCCGCT--A  
hSREBP-1a       GGCCGGCTGAGGGGAGATTTGTGGCGCAGACCGGGGATCAGGGGTCCCCCGCTCTCTCAA -71 
                 *   **                   *** *   **   * *    *    * * **  * 
 
rSREBP-1a       GGTAAGCTGGCTGGATGTCCCGCTGGTNNNNNNNNNNNNNNNNNNNNNNCGCCCCTCCGC  
mSREBP-1a       GGCGAGCTGTCAGGATGCAGGCTGGTGGGCGGGGCTTGATGGGAAACCCCGCCCCTCCGC  
hSREBP-1a       GGTGGGGCGGGGCCGTCTATCTGGGAGGGCGGGTCCTCCCCGAAAGGCCCCGCCTCCGCC -11 
                **   *  *      *           ****** *      * **  ***  **  *  * 
 
rSREBP-1a       TCAGGTGGCT----------CCGCCCGCGGAACCCGGTTTCCCAGGAACTTTTCGTTAAC  
mSREBP-1a       TCAGGTGGCT----------CCGCCCGCGGAACCCAGTTTCCGGGGAACTTTTCCTTAAC  
hSREBP-1a       TCGACCGCCCAGCAGAGCTGCGGCCGGGGGAACCCAGTTTCCGAGGAACTTTTCGCCGGC +50 
                **    * *           * *** * ******* ******  **********     * 
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Fig. 2. SP1 binding sites are critical for the human SREBP-1a promoter activity. (A) A partial sequence alignment of the rat, mouse and human
SREBP-1a promoters: the putative SP1, NF-Y and NFjB binding sites are underlined. The human SREBP-1a mRNA initiation site is denoted by an
arrow. (B) Reporter gene analysis following the transfection of HEK293T cells with wild-type or indicated SP1 binding sites mutants. The data are
represented as the mean ﬁreﬂy/renilla luciferase ratio relative to the activity of the p 75/+194luc construct (set at 100%). Each point is the
means ± S.E.M. of four assays runs in duplicate. **P < 0.01. (C) HEK293T cells were transiently transfected with p 360/+194luc plasmid or site-
speciﬁc mutants, and were analyzed as above.
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with 2 lg of the corresponding antibodies against SP1 (sc-59),
EGR-1 (sc-110) and RNA pol II (sc-899) (Santa Cruz). Immunoselect-
ed chromatin was eluted and formaldehyde cross-linking was reverted.
The DNA from all samples was puriﬁed with a PCR puriﬁcation kit
(Qiagen) and used for PCR analysis. The PCR primers used to
detect target sequences were as follows: SREBP-1a (promoter),
5 0-ACTCGGCTTCCTTGCTTGGTGCTG-3 0 and 5 0-CGCCGGCG-
AAAAGTTCCTCGGA-30; SREBP-1a (coding region), 5 0-AGCTTA-
CAGCACAGAACTCCCCTG-3 0 and 5 0-CCCCTGTGGAGCACAT-
GGTG-3 0; a-actin (promoter), 5-TCCAGGTCTAGCCAGTCCTG-3 0
and 5 0-AAAGCTGAGCCACGTCGACC-3 0; b-actin(promoter),
5 0- TGCACTGTGCGGCGAAGC-3 0 and 5 0-TCGAGCCATAAAA-
GGCAA-30. Each ChIP assay was performed at least twice to ensure
reproducibility, and the linearity of the semi-quantitative PCR analysis
was routinely measured for the diﬀerent genes.
2.6. Statistical analysis
Statistical signiﬁcance was estimated with the Students two-tailed t-
test for unpaired observations. A P value of less than 0.05 was consid-
ered to be signiﬁcant.3. Results
3.1. Functional analysis of the 5 0 ﬂanking region of the human
SREBP-1a promoter
We investigated the regulation of the human SREBP-1a
promoter by generating a series of progressive 5 0 deletion
reporter gene constructs, that extended over 2 kb of the
ATG translation start site (expressed as +1), and we then
proceeded to transfect these constructs into HEK293T cells.
Firstly, we conﬁrmed that this cell line expressed the expected
SREBP-1 proteins with a majority SREBP-1a transcript
expression (Fig. 1A). Analysis of reporter constructs revealed
that a region at 75 bp upstream of the ATG start codon was
suﬃcient to retain full promoter activity (Fig. 1B). Fig. 2A
shows the human SREBP-1a promoter region between nucleo-
tides 310 and +285, along with some putative binding sitesmB
mC
mA CTCTCAAGGTctttgGaGGCCGTCTATCTGGGAGGG
CCGTCTATCTGGGAtGGaGG
-77 CTCTCAAGGTGGGGCGGGGCCGTCTATCTGGGAGGGCGG
SP1 (A) SP1 (B
Probe A
Probe B
- +    +     +    + - + rhSP1
- - wt mAAb - -Competitor
AProbe
Fig. 3. SP1 transcription factor binds to the minimal human SREBP-1a prom
panel. The sequence of the human SREBP-1a core promoter and the sequence
generated in the probes are noted in the lower case. The white arrow denote
SP1 binding signal.for transcriptional regulators which were predicted by
TRANSFAC database analysis. This promoter sequence did
not contain a TATA box while various GC boxes were iden-
tiﬁed, which could be potential binding sites for SP1 family
members. In order to verify the contribution of the GC-boxes
to the overall activation, we generated single, double or triple
mutant reporter plasmids (Fig. 2B). Upon transient transfec-
tion into HEK293T cells, a dramatic drop in the reporter
activity was observed in the single mutant, which we named
C, or in the double or triple mutants, with a luciferase activ-
ity similar to the pGL3-basic vector. These data indicated a
major, if not exclusive, transcriptional activation from the
GC boxes. Furthermore, the 3 0-site appears to be crucial
for promoter activity in HEK293T cells. The computer anal-
ysis (TRANSFAC) of the human SREBP-1a promoter pre-
dicted two putative nuclear factor kappa B (NFjB) binding
sites and a CCAAT box (a NF-Y binding site) immediately
upstream of the GC boxes, that were not present in the
mouse or rat sequences (Fig. 2A). However, a mutation of
these putative elements did not reduce promoter activity sig-
niﬁcantly (Fig. 2C).
3.2. Identiﬁcation of SREBP-1a activators
In order to evaluate whether the GC boxes of the 77 to
1 bp minimal promoter region bind SP1 transcription fac-
tors, three oligonucleotides (indicated as probes A, B or C in
Fig. 3) were used in the EMSA assay in the presence of recom-
binant human SP1 protein. The three SP1 binding sites were
well recognized by the SP1 factor since the complex was abol-
ished in the presence of unlabelled oligonucleotides, and was
partially supershifted with an anti-SP1 monoclonal antibody.
Moreover, competition was not observed when SP1-mutated
oligonucleotides were used (see lanes mA, mB and mC). These
results demonstrate that the putative SP1 elements, essential
for basal human SREBP-1a promoter activity, bind the SP1
transcription factor in vitro.-1
GTCCTCCCCGAAAGGC
CCTCCCCGAAAGGaCtttCCTCCGCCTCGACCGCCC
GTCCTCCCCGAAAGGCCCCGCCTCCGCCTCGACCGCCC
) SP1 (C)
Probe C
   +    +     + - +     +     +    +
wt mBAb - - wt mCAb
CB
oter. An autoradiogram from a typical EMSA is shown in the bottom
s for individual probes used in the EMSA studies are shown. Mutations
s SP1 binding signal, while the black arrow represents the supershifted
A. Ferna´ndez-A´lvarez et al. / FEBS Letters 582 (2008) 177–184 1813.3. Overlapping SP1/EGR-1 elements regulate the human
SREBP-1 a promoter
We observed that the sequence between 77 and 1 bp con-
tained overlapping binding sites for SP1 and EGR-1 (Fig. 4A).
We examined competition for binding using oligonucleotides
A, B and C described in Fig. 3. When DNA probes were mixed
with either protein factor alone, single complexes of character-
istic migration rates were detected (Fig. 4B). Both SP1 and
EGR-1 bound separately and speciﬁcally to DNA fragments
when presented together. An EGR-1 speciﬁc antibody
removed only the lower retarded band corresponding to
EGR-1 without disturbing SP1 binding. Then, we also tested
whether EGR-1 could bind to this region by competing with
SP1 to the three GC elements. When increasing amounts ofCTCTCAAGGTGGGGCGGGGCCGTCTATCTGGGAGGGCGGG
SREBP 1a (promoter)
SREBP 1a (coding)
Inpu
t
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Fig. 4. SP1/EGR-1 binding to overlapping sites in the human SREBP-1a pr
promoter, along with locations of the putative overlapping SP1/EGR-1 eleme
standard gel shift analysis as described in Section 2. Labelled probes, whose s
with both proteins together prior to electrophoresis, as indicated at the top
speciﬁc antibodies. (C) A representative autoradiogram of three independent
nuclear extracts, prepared from HEK293T cells transiently transfected with a
in nuclear extracts from cells transfected with native control (lane 1) or E
prepared from HEK293T cells. The PCR analysis of DNA extracted fro
antibodies, and of the samples treated without an antibody (NoAb), using am
shown. A PCR analysis of the promoter regions of the a- and b-actin gen
analysis, respectively, is also shown.EGR-1 were added with a constant amount of SP1, EGR-1
was preferentially bound to each GC element in the promoter
to compete with SP1 at its binding sites (Fig. 4C).
To verify the in vivo binding of the transcription factors SP1
and EGR-1 in the SREBP-1a promoter, we carried out a ChIP
assay in growing HEK293T cells. After immunoprecipitation
and cross-link reversal, enrichment of the human SREBP-1a
promoter was monitored by PCR ampliﬁcation using speciﬁc
primers for the promoter region 277 to +51 (Fig. 4D). Fac-
tors SP1 and EGR-1 were present in the human SREBP-1a
promoter, whereas we were unable to precipitate the DNA
fragments corresponding to the SREBP-1a coding region. In
order to verify the results obtained, the same samples
employed for the ChIP assay were used for the RNApol-ChIPTCCTCCCCGAAAGGCCCCGCCTCCGCCTCGACCGCCC
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equences were described in Fig. 3, were incubated with EGR-1 alone or
of the ﬁgure. Identity of protein–DNA complexes was ensured using
experiments shows competition for SP1 binding by increasing levels of
pcDNA3-egr1 expression vector. Western blot analysis of EGR-1 levels
gr-1 expression vector (lane 2) is shown. (D) Soluble chromatin was
m input samples (input), the immunoprecipitates with the indicated
plicons from the promoter or coding regions of the indicated genes, is
es, as positive and negative controls of the ChIP and RNApol ChIP
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antibody precipitated both promoter and coding chromatin
fragments, thus conﬁrming that the SREBP-1a transcript is ex-
pressed in HEK293T cells.
In the light of the results obtained, we evaluated whether
EGR-1 directly aﬀects the human SREBP-1a promoter activ-
ity. As Fig. 5A depicts, EGR-1 is able to inhibit the 75/
+194luc SREBP-1a luciferase activity. The EGR-1 overexpres-
sion was able to increase the luciferase activity of the pEB-
S14luc reporter vector as a positive control. This plasmid
encompasses four binding sites for EGR-1 derived from the
egr-1 promoter immediately upstream of the TATA box [5].
The essential role of SP-1 in the positive regulation of the hu-
man SREBP-1a promoter was also evaluated in HEK293T
cells in transient transfection experiments (Fig. 5B). The
expression of SP1 led to increased luciferase reporter activity
under the control of the SREBP-1a promoter. A reporter gene,
under the control of four copies of a GC-rich genetic element0
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Fig. 5. EGR-1 overexpression represses the human SREBP-1a pro-
moter. Reporter plasmids and the pcDNA-egr1 (panel A) or pCMV-
Sp1 (panel B) expression vector were transiently co-transfected into
HEK293T cells. After 24 h, cells were lysed to measure luciferase
activities. The EGR-1 data are represented as the mean ﬁreﬂy/renilla
luciferase ratio relative to the activity of the empty expression vector
(set at 100%). For the Sp1 analysis, the mean ﬁreﬂy luciferase/protein
ratio was considered. Values represent the means ± S.E.M. of four
transfections run in duplicate; **P < 0.01; *P < 0.05.of the aldolase C gene, a TATA box, and the luciferase open
reading frame (pALd-GCB4), was used as an SP1-dependent
luciferase expression vector [5].
To conﬁrm the inhibitor role of EGR-1, HEK293T cells
were transfected with gene-speciﬁc siRNA. After transfection
with siRNA, the mRNA expression of egr-1 was speciﬁcally
knocked down by 75% (Fig. 6B). In contrast, the promoter
activity of the 75 bp fragment, or the endogenous SREBP-
1 expression, was signiﬁcantly higher than those obtained in
cells transfected with the siRNA control (Fig. 6A and B).
However, the activity of the EGR-1 positive pEBS14luc repor-
ter vector diminished. The reciprocal eﬀect was observed after
speciﬁcally knocking down SP1.4. Discussion
In this report, we have identiﬁed the core human SREBP-1a
promoter region. The human promoter, like the mouse pro-
moter [4], is enclosed in a small region of DNA that is charac-
terized by a GC-rich region. Adamson et al. proposed three
‘‘levels of certainty’’ for the identiﬁcation of EGR-1 target
genes [12]: (i) a correlation of the egr-1 expression with the
indicated gene using egr-1 inducible signal molecules or egr-1
expression vectors (level 1); (ii) the in vitro identiﬁcation of
EGR-1 binding to the promoter of the gene (level 2) and (iii)
the in vivo veriﬁcation of EGR-1 binding by the chromatin
immunoprecipitation assay (level 3). Having followed the three
aforementioned levels (Figs. 4 and 5), our studies revealed that
the EGR-1 and SP1 binding sites overlap within the SREBP-1a
proximal promoter. These overlapping sites are present in
other promoters, in most of which the binding of both tran-
scription factors is mutually exclusive [6]. The data in Fig. 4
show that elevated amounts of EGR-1 can displace pre-bound
SP1 from the GC elements. Moreover, the three GC boxes do
not have the same EGR-1 binding capacity. EGR-1 binds
more eﬃciently to probe C in comparison with probes A and
B (Fig. 4C). This main role of the 3 0 site was also described
in the mouse core SREBP-1a promoter [4], thus emphasizing
that this element is essential for the regulated expression of
the SREBP-1a transcript.
There are well documented examples of the dual role of
EGR-1 as either an activator or transcriptional repressor
[13]. Our evidence suggests that EGR-1 functions as a tran-
scriptional repressor for the human SREBP-1a promoter. This
inhibitor role was speciﬁc for the SREBP-1a promoter because
a forced expression of egr-1 slightly increased the activity of
the human SREBP-1c promoter (Fig. 5A).
Egr-1 is widely expressed and regulates a range of cellular
processes, including proliferation, growth and apoptosis [14].
The proposed role of EGR-1 in controlling cell growth is based
on the correlation between the mitogenic response and EGR-1
biosynthesis. However, the fact that the overexpression of egr-
1 neither induces cell death nor proliferation suggests that
EGR-1 alone is insuﬃcient to induce changes in physiological
parameters [14]. Recently, Nakakuki et al. reported that
SREBP-1a regulates cell growth [15]. The authors pointed
out the biphasic eﬀects of SREBP-1a, depending on its nuclear
amount; at low expression levels, it promotes proliferation,
whereas an overexpression of SREBP-1a blocks cell growth.
The regulation of the SREBP-1a expression exercised by
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Fig. 6. Knockdown experiments conﬁrm the reciprocal regulation of the human SREBP-1a by EGR-1 and Sp1. (A) HEK293T cells transfected with
reporter plasmids and speciﬁc siRNAs. The fold induction relative to the pGL3-basic vector (±S.E.M.), normalized to renilla luciferase data, was
calculated. The results shown are the average of four transfections run in duplicate; **P < 0.01; *P < 0.05. (B) The Egr-1, Sp1 or SREBP-1a
expression, normalized to the GAPDH expression, on HEK293T cells after transfection with gene-speciﬁc siRNAs. Asterisks indicate a signiﬁcant
diﬀerence (*P < 0.05; **P < 0.01) compared with cells with the negative siRNA control used as a calibrator.
A. Ferna´ndez-A´lvarez et al. / FEBS Letters 582 (2008) 177–184 183EGR-1, and proved in our study, would reveal new aspects to
be taken into account in the control of cell cycle and growth.
In conclusion, we have performed a functional characteriza-
tion of the human SREBP-1a promoter, and have mapped the
basal promoter region required for transcriptional activation.
Furthermore, we have pointed out the functional role of the
three GC-boxes containing overlapping EGR-1/SP1 binding
sites.
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